Compare Davita Inc (DVA) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs First Citizens BancShares Inc — how do they compare? Davita Inc trades at $180.81 (market cap $11.58B), while First Citizens BancShares Inc trades at $2,277.11 (market cap $25.26B). The key difference: First Citizens BancShares Inc is far larger — about 2.2× Davita Inc's market cap, and First Citizens BancShares Inc pays a 0.37% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | FCNCA | |
|---|---|---|
Market Cap | $11.58B | $25.26B |
Sector | Health | Sector/Thematic |
52-Week High | $240.96 | $2.27K |
52-Week Low | $103.87 | $1.64K |
Enterprise Value | $24.30B | — |
Dividend Yield | — | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $181.72, down 1.07% on the day, with technical indicators showing a mixed but overall bullish signal. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.02 surpassing estimates. Revenue growth is steady, reaching $13.64B in 2025, though net income margin has fluctuated. Analyst sentiment is cautiously optimistic with a consensus price target of $232.25, representing significant upside potential from current levels.
The outlook for DVA is positive, driven by strong volume growth and strategic execution, but faces risks from reimbursement pressures and a high debt load. Investment opportunity lies in the valuation discount to analyst targets and consistent earnings beats, while key risks include payer mix challenges and macroeconomic factors affecting healthcare spending.
First Citizens BancShares (FCNCA) trades at $2,271.31, up 1.7% on the day, with a bullish technical signal from moving averages and recent earnings beats. The stock shows strong fundamentals with a P/E of 12.08 and net income margin of 25.23%, supported by consistent revenue around $9.3B. Recent news highlights expansion in commercial lending and strategic leadership appointments, reinforcing growth initiatives.
Outlook remains positive due to earnings momentum and dividend stability, but risks include elevated uninsured deposits and net interest margin pressure. Analyst consensus is cautious with 82% hold ratings, suggesting limited near-term upside despite a $2,310 price target. Investors should weigh solid profitability against sector headwinds and valuation constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
